Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Savara's Phase 3 IMPALA-2 Trial Of Molgramostim Met Statistical Significance For Primary Endpoint And Multiple Secondary Endpoints In Autoimmune Pulmonary Alveolar Proteinosis

Author: Benzinga Newsdesk | June 26, 2024 06:33am

Statistically Significant Improvement in Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Versus Placebo at Week 24 (Primary Endpoint) and Week 48 (Secondary Endpoint).
Statistically Significant Improvement in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 24 (Secondary Endpoint).
97% of Patients Completed Double-Blind Treatment Through Week 48 with No Trial Drug Related Adverse Events Leading to Discontinuation.
100% of Patients Completing the 48-Week Double-Blind Period Elected to Participate in the 96-Week Open-Label Period.
Company Plans to Complete BLA Submission in 1H 2025.

Posted In: SVRA